Key Highlights

  • ONE Nuclear Energy (NASDAQ:ONEN) was up 7.94 percent to USD 1.36; the last close was USD 1.31.
  • Netcapital (NASDAQ:NCPL) was up 11.95 percent to USD 1.78; annual and quarterly reports are overdue.
  • LiveWire (NYSE:LVWR) was up 10.61 percent to USD 0.73; management disclosed substantial doubt about going concern.
  • Blue Gold (NASDAQ:BGL) was up 7.99 percent to USD 0.1271; the prior close was USD 0.1177.
  • Milestone Pharmaceuticals (NASDAQ:MIST) was up 9.32 percent to USD 0.7980; a Nasdaq bid price notice set an April 21, 2027 deadline.
  • Lichen International (NASDAQ:LICN) was up 8.40 percent to USD 0.6166; fiscal 2025 Revenue fell about 40.89 percent.

ONE Nuclear Energy (NASDAQ:ONEN): A Recent Listing Bounces

ONE Nuclear Energy (NASDAQ:ONEN) shares were up 7.94 percent to USD 1.36 in pre-market trading on November 2, 2026, against a previous close of about USD 1.31. No announcement dated late October or November 2, 2026 was identified. The Business combination closed on September 23, 2026.

The company said its Louisiana portfolio totals about 5 GW in active development, including a nuclear project of up to 1 GW. As a penny stock, it carries Volatility and dilution risk, and nuclear projects face long permitting timelines.

Netcapital (NASDAQ:NCPL): Rebound Despite Filing Delays

Netcapital (NASDAQ:NCPL) was up 11.95 percent to USD 1.78 in pre-market trading on November 2, 2026. No company announcement explaining the move was identified. Nasdaq confirmed on October 7, 2026 that the minimum bid price requirement was regained.

The Annual Report for the year ended April 30, 2026 and the July 2026 Quarterly Report remain unfiled, and Nasdaq may not accept the company's remediation plan. The prior auditor resigned effective August 12, 2026, and the company has until February 9, 2027 to file the annual report. Fiscal 2025 revenue was USD 869 thousand with a net loss of USD 28.3 million.

LiveWire (NYSE:LVWR): A Bounce After a Going Concern Warning

LiveWire (NYSE:LVWR) was up 10.61 percent to USD 0.73 in pre-market trading on November 2, 2026. No new company release was found, and the move appears to be a bounce after earlier weakness. On October 29, 2026 the company reported third quarter revenue of USD 7.9 million, up 38 percent, and withdrew its 2026 operating loss guidance.

Cash was USD 39.9 million at September 30, 2026, versus USD 82.8 million at December 31, 2025, and management disclosed substantial doubt about its ability to continue as a going concern. The chief executive resigned effective October 21, 2026, and a Special Restructuring Committee was formed. A related-party term Loan of USD 76.8 million is due December 2027.

Blue Gold (NASDAQ:BGL): A Sub-Dime Stock Recovers Ground

Blue Gold (NASDAQ:BGL) was up 7.99 percent to USD 0.1271 in pre-market trading on November 2, 2026, a gain of about USD 0.0094 per share (calculated). No announcement from late October or November 2, 2026 was identified. The shares fell 3.45 percent on October 14 and 9.83 percent on October 15, 2026.

Market capitalisation was about USD 5.36 million at the last close. The stock is a penny stock, and the platform depends on a banking partner not yet confirmed.

Milestone Pharmaceuticals (NASDAQ:MIST): Bouncing After a Nasdaq Notice

Milestone Pharmaceuticals (NASDAQ:MIST) was up 9.32 percent to USD 0.7980 in pre-market trading on November 2, 2026. No company announcement dated November 2, 2026 was identified. A Nasdaq notice dated October 23, 2026 gives the company until April 21, 2027 to regain the USD 1.00 minimum bid price.

Second quarter 2026 product revenue from CARDAMYST was USD 559 thousand, with a net loss of USD 28.6 million. Cash and investments were USD 170.6 million at June 30, 2026, which the company said should fund operations into the second half of 2027.

Lichen International (NASDAQ:LICN): A Bounce After a Rough Stretch

Lichen International (NASDAQ:LICN) was up 8.40 percent to USD 0.6166 in pre-market trading on November 2, 2026. The implied prior close was about USD 0.57 (calculated), and shares were quoted near USD 0.81 in an October 2026 snapshot. No company announcement explaining the move was identified.

Fiscal 2025 revenue fell about 40.89 percent to roughly USD 24.52 million, which the company attributed to price competition. Shareholders approved a reverse split range of 1-for-20 to 1-for-200 on February 12, 2025.

Where Things Stand

All six names rose pre-market, yet most had no identified company announcement, and each carries a stated weakness, from overdue filings and a going concern warning to bid price notices and falling revenue. Readers may watch for Nasdaq responses, financing disclosures and quarterly reports. Whether the bounces hold in regular trading will be the first test.